0001179110-19-002313.txt : 20190222 0001179110-19-002313.hdr.sgml : 20190222 20190222161126 ACCESSION NUMBER: 0001179110-19-002313 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190220 FILED AS OF DATE: 20190222 DATE AS OF CHANGE: 20190222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Myer Vickesh CENTRAL INDEX KEY: 0001742806 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37687 FILM NUMBER: 19625808 MAIL ADDRESS: STREET 1: C/O EDITAS MEDICINE, INC. STREET 2: 11 HURLEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Editas Medicine, Inc. CENTRAL INDEX KEY: 0001650664 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464097528 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-401-9000 MAIL ADDRESS: STREET 1: 11 HURLEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02141 4 1 edgar.xml FORM 4 - X0306 4 2019-02-20 0 0001650664 Editas Medicine, Inc. EDIT 0001742806 Myer Vickesh C/O EDITAS MEDICINE, INC. 11 HURLEY ST. CAMBRIDGE MA 02141 0 1 0 0 Chief Technology Officer Common Stock 2019-02-20 4 M 0 3000 0.65 A 3000 D Common Stock 2019-02-20 4 S 0 3000 20.42 D 0 D Stock Option (right to buy) 0.65 2019-02-20 4 M 0 3000 0 D 2025-04-29 Common Stock 3000 76307 D The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017. This transaction was executed in multiple trades at prices ranging from $20.31 to $20.56. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected. This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019. /s/ Anthony Joyce, attorney-in-fact 2019-02-22